Orakl Oncology

Patient-derived organoids, clinical data and AI for oncology drug development.

Orakl Oncology is known for patient-derived organoids, clinical data and AI for oncology drug development. It is based in Paris, France, is at the Series A stage with $50M raised, and sits in our Oncology category.

orakl-oncology.com

What they do

Orakl Oncology, a Gustave Roussy spin-out founded in 2023, combines patient-derived tumor organoids, clinical histories and AI to support oncology drug-development decisions before clinical trials. On November 12, 2026, it announced an oversubscribed $34 million Series A co-led by Norrsken VC and Singular, bringing total funding to $50 million. New investors include InfraVia, Serena, the Patient Autonome Fund managed by Bpifrance, teampact.ventures and Plug and Play. Norrsken reports 18 of the top 20 pharmaceutical companies in its commercial pipeline; a pipeline is not a count of signed customers. The April 2026 SCOPE medRxiv preprint, not peer reviewed, validated trial-arm predictions against 32 arms from 23 published trials. Median progression-free survival predictions had a mean absolute error of 0.82 months and R squared of 0.85; the model identified the superior arm in 7 of 8 head-to-head comparisons. These are trial-arm results, not verified individual-patient predictions. In July 2026, Orakl announced exclusive rights to evaluate four Sanofi oncology assets.

Source announcement